Physician profile
Brent P Goodman
NPI 1457334799
$198,478.46
in general payments reported to CMS, 2019-2025
11 companies · $172K in 2025
The $172K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.09 · 2023: $2,685 · 2024: $24K · 2025: $172K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $154K · Travel and Lodging: $29K · Consulting Fee: $12K · Food and Beverage: $2,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $153,640.00 |
| Travel and Lodging | $29,476.62 |
| Consulting Fee | $12,351.00 |
| Food and Beverage | $2,964.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $198,164.23 | 2023-2025 | Wainua |
| Pharming Healthcare, INC. | $89.69 | 2024 | Ruconest |
| Argenx US, INC. | $47.91 | 2024 | Vyvgart Hytrulo |
| Akcea Therapeutics, INC. | $46.09 | 2019 | |
| Alexion Pharmaceuticals, INC. | $35.00 | 2024 | Ultomiris |
| Cycle Pharmaceuticals INC | $28.47 | 2024 | Sajazir |
| Biocryst US Sales Co., LLC | $26.85 | 2024 | Orladeyo |
| Grifols USA, LLC | $22.22 | 2024 | Gamunex-C |
| Blueprint Medicines Corporation | $18.00 | 2024 | Ayvakit |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.